"The Institute is a combination of clinical care and scientific research, with patients and their families at the center of these efforts. Recognized nationally and internationally for its cancer (especially pancreatic cancer), heart, bariatric and genetic research, the Institute has assembled a team of physicians, scientists and clinical experts to generate solutions to challenging diseases and disorders."

During the past decade, Honor Health Research Institute conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 11 clinical trials were completed, i.e. on average, 31.4% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 7 clinical trials were completed. i.e. 53.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Honor Health Research Institute" #1 sponsor was "Celgene" with 3 trials, followed by "Rhythm Pharmaceuticals, Inc." with 3 trials sponsored, "Biosense Webster, Inc." with 2 trials sponsored, "Genentech, Inc." with 2 trials sponsored and "Incyte Corporation" with 2 trials sponsored. Other sponsors include 28 different institutions and companies that sponsored additional 37 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Honor Health Research Institute" #1 collaborator was "Sanofi" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Johns Hopkins University" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Honor Health Research Institute" are "Solid Tumor" (4 trials), "Advanced Solid Tumors" (3 trials), "Breast Cancer" (3 trials), "Cancer" (3 trials) and "Solid Tumors" (3 trials). Many other conditions were trialed in "Honor Health Research Institute" in a lesser frequency.

Most popular intervention types in "Honor Health Research Institute" are "Drug" (39 trials), "Device" (6 trials), "Biological" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (5 trials), "Carboplatin" (3 trials), "Setmelanotide" (3 trials), "Atezolizumab" (2 trials) and "CC-486" (2 trials). Other intervention names were less common.

The vast majority of trials in "Honor Health Research Institute" are 45 trials for "All" genders.

Currently, there are NaN active trials in "Honor Health Research Institute". undefined are not yet recruiting, 11 are recruiting, 6 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 18 completed trials in Honor Health Research Institute, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Honor Health Research Institute, 30 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".